Advanced search
Publication Cover
Leukemia & Lymphoma Volume 31, 1998 - Issue 5-6
Submit an article Journal homepage
116
Views
57
CrossRef citations to date
0
Altmetric
Original Article

Results of Topotecan Single-Agent Therapy in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Miloslav Beran Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Elihu Estey Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Susan M. O'brien Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Francis J. Giles Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Charles A. Roller Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Steven Kornblau Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
,
Michael Keating Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
&
Hagop M. Kantarjian Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
 show all
Pages 521-531 | Received 24 Mar 1998, Published online: 01 Jul 2009

Citations (57)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Thomas P. Thomopoulos, Anthi Bouhla, Sotirios G. Papageorgiou & Vasiliki Pappa. (2021) Chronic myelomonocytic leukemia - a review. Expert Review of Hematology 14:1, pages 59-77.
Read now
Azra Raza, Laurie Lisak, Jennifer Billmeier, Hassan Pervaiz, Muhammad Mumtaz, Samreen Gohar, Khalid Wahid & Naomi Galili. (2006) Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leukemia & Lymphoma 47:3, pages 433-440.
Read now
Jorge Cortes, Elihu Estey, Miloslav Beran, Susan O'brien, Francis Giles, Charles Roller, Michael Keating & Hagop Kantarjian. (2000) Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia. Leukemia & Lymphoma 36:5-6, pages 479-484.
Read now

Articles from other publishers (54)

Mrinal M. Patnaik & Ayalew Tefferi. (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology 97:3, pages 352-372.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2019) Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology 95:1, pages 97-115.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2018) Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. American Journal of Hematology 93:6, pages 824-840.
Crossref
Eric Solary & Raphael Itzykson. (2017) How I treat chronic myelomonocytic leukemia. Blood 130:2, pages 126-136.
Crossref
Sonja Burgstaller. (2016) Treatment of chronic myelomonocytic leukemia. memo - Magazine of European Medical Oncology 9:4, pages 168-171.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2016) Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. American Journal of Hematology 91:6, pages 631-642.
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2016) Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings 91:2, pages 259-272.
Crossref
Ali N. Chamseddine, Elias Jabbour, Hagop M. Kantarjian, Zachary S. Bohannan & Guillermo Garcia-Manero. (2015) Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Current Oncology Reports 18:1.
Crossref
Kristen B. McCullough & Mrinal M. Patnaik. (2015) Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update. Current Hematologic Malignancy Reports 10:3, pages 292-302.
Crossref
Christopher B. Benton, Aziz Nazha, Naveen Pemmaraju & Guillermo Garcia-Manero. (2015) Chronic myelomonocytic leukemia: Forefront of the field in 2015. Critical Reviews in Oncology/Hematology 95:2, pages 222-242.
Crossref
Mrinal M. Patnaik, Sameer A. Parikh, Curtis A. Hanson & Ayalew Tefferi. (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. British Journal of Haematology 165:3, pages 273-286.
Crossref
Lisa Pleyer, Ulrich Germing, Wolfgang R. Sperr, Werner Linkesch, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Martin Schreder, Michael Pfeilstocker, Alois Lang, Thamer Sliwa, Dietmar Geissler, Konstantin Schlick, Gudrun Placher-Sorko, Georg Theiler, Josef Thaler, Martina Mitrovic, Daniel Neureiter, Peter Valent & Richard Greil. (2014) Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research 38:4, pages 475-483.
Crossref
Ramon V. Tiu & Mikkael A. Sekeres. (2014) Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. Current Opinion in Hematology 21:2, pages 131-140.
Crossref
Sameer A. Parikh & Ayalew Tefferi. (2013) Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology 88:11, pages 967-974.
Crossref
Rafael BejarRamon V. TiuMikkael A. SekeresRami S. Komrokji. (2013) Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. American Society of Clinical Oncology Educational Book:33, pages e256-e270.
Crossref
Gopi K Prithviraj, Blessy M Mathew, Rami K Komrokji, Alan F List & Eric Padron. (2013) Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment. International Journal of Hematologic Oncology 2:2, pages 151-162.
Crossref
Sonja Burgstaller. (2013) Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications. memo - Magazine of European Medical Oncology 6:1, pages 32-36.
Crossref
Julia Moukharskaya & Claire Verschraegen. (2012) Topoisomerase 1 Inhibitors and Cancer Therapy. Hematology/Oncology Clinics of North America 26:3, pages 507-525.
Crossref
Sameer A. Parikh & Ayalew Tefferi*. (2012) Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology 87:6, pages 610-619.
Crossref
H Cheng, V G Kirtani & U Gergis. (2011) Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplantation 47:4, pages 535-541.
Crossref
Michael Newton, Gene Wetzstein & Daniel Sullivan. 2011. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures 103 123 .
Lisa Pleyer, Daniel Neureiter, Victoria Faber & Richard Greil. 2010. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes 223 233 .
P.W. Wijermans, B. Rüter, M.R. Baer, J.L. Slack, H.I. Saba & M. Lübbert. (2008) Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia Research 32:4, pages 587-591.
Crossref
Nienke A. de Vries, Mariët Ouwehand, Tessa Buckle, Jos H. Beijnen & Olaf van Tellingen. (2007) Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed‐phase high‐performance liquid chromatography. Biomedical Chromatography 21:11, pages 1191-1200.
Crossref
Michelle A. ElliottMDMD. (2006) Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Practice & Research Clinical Haematology 19:3, pages 571-593.
Crossref
Ayalew Tefferi, Michelle A. Elliott & Animesh Pardanani. (2006) Atypical Myeloproliferative Disorders: Diagnosis and Management. Mayo Clinic Proceedings 81:4, pages 553-563.
Crossref
Jonathan E. Kolitz. 2006. Oncology. Oncology 1160 1181 .
Hussain I. Saba & Pierre W. Wijermans. (2005) Decitabine in Myelodysplastic Syndromes. Seminars in Hematology 42, pages S23-S31.
Crossref
F FOSS. (2004) Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 17:4, pages 573-584.
Crossref
Javier Bolaños-Meade, Chuanfa Guo, Ivana Gojo & Judith E Karp. (2004) A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leukemia Research 28:6, pages 571-577.
Crossref
M. Beran. (2004) Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research 28:5, pages 443-446.
Crossref
Francis J Giles, Jorge E Cortes, Hagop M Kantarjian, Susan M O’Brien, Elihu Estey & Miloslav Beran. (2004) A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leukemia Research 28:4, pages 353-357.
Crossref
Francis J. Giles, Martin S. Tallman, Guillermo Garcia-Manero, Jorge E. Cortes, Deborah A. Thomas, William G. Wierda, Srdan Verstovsek, Marta Hamilton, Emma Barrett, Maher Albitar & Hagop M. Kantarjian. (2004) Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100:7, pages 1449-1458.
Crossref
Daniel A Vaena, Paul Walker, Kenneth Pennington, Anthony Stephens, Michael J Stender, Constantin T Yiannoutsos, Carol Young, Cindy Stoner & Larry D Cripe. (2004) Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leukemia Research 28:1, pages 49-52.
Crossref
R A Nagourney, B L Sommers, S M Harper, S Radecki & S S Evans. (2003) Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. British Journal of Cancer 89:9, pages 1789-1795.
Crossref
Douglas J Weiss. (2003) New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. Veterinary Clinics of North America: Small Animal Practice 33:6, pages 1317-1334.
Crossref
Blake Tomkinson, Ray Bendele, Francis J. Giles, Eric Brown, Atherton Gray, Karen Hart, Jeremy D. LeRay, Denny Meyer, Michelle Pelanne & David L. Emerson. (2003) OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leukemia Research 27:11, pages 1039-1050.
Crossref
Peter Valent, Friedrich Wimazal, Ilse Schwarzinger, Wolfgang R. Sperr & Klaus Geissler. (2003) Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)Pathogenese, Klassifikation und Therapie der myelodysplastischen Syndrome. Wiener Klinische Wochenschrift 115:13-14, pages 515-536.
Crossref
Francis J. GilesStefan FaderlDeborah A. ThomasJorge E. CortesGuillermo Garcia-ManeroDan DouerAlexandra M. LevineCharles A. KollerSima S. JehaSusan M. O’BrienElihu H. EsteyHagop M. Kantarjian. (2003) Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 21:6, pages 1050-1056.
Crossref
E. J. Feldman. 2003. Acute Leukemias IX. Acute Leukemias IX 161 164 .
Jeffrey Gryn, Zella R. Zeigler, Richard K. Shadduck, John Lister, Jane M. Raymond, Ibrahim Sbeitan, Charles Srodes, Dennis Meisner & Cynthia Evans. (2002) Treatment of myelodysplastic syndromes with 5-azacytidine. Leukemia Research 26:10, pages 893-897.
Crossref
Razelle Kurzrock. (2002) Myelodysplastic syndrome overview. Seminars in Hematology 39:3, pages 18-25.
Crossref
Xavier Thomas. (2002) Nouvelles approches thérapeutiques des leucémies aiguës de l'adulte. Revue Française des Laboratoires 2002:344, pages 55-65.
Crossref
Lewis R. SilvermanErin P. DemakosBercedis L. PetersonAlice B. KornblithJimmie C. HollandRosalie Odchimar-ReissigRichard M. StoneDouglas NelsonBayard L. PowellCarlos M. DeCastroJohn EllertonRichard A. LarsonCharles A. SchifferJames F. Holland. (2002) Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. Journal of Clinical Oncology 20:10, pages 2429-2440.
Crossref
Alan F. List. (2002) New Approaches to the Treatment of Myelodysplasia. The Oncologist 7:S1, pages 39-49.
Crossref
HA Rossi, J O'Donnell, F Sarcinelli, FM Stewart, PJ Quesenberry & PS Becker. (2002) Granulocyte–macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 16:3, pages 310-315.
Crossref
Seung Tae Lee, Joon Ho Jang, Hyung Chan Suh, Jee Sook Hahn, Yun Woong Ko & Yoo Hong Min. (2001) Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high‐risk myelodysplastic syndrome. American Journal of Hematology 68:4, pages 237-245.
Crossref
Miloslav Beran, Yu Shen, Hagop Kantarjian, Susan O'Brien, Charles A. Koller, Francis J. Giles, Jorge Cortes, Deborah A. Thomas, Stefan Faderl, Simona Despa & Elihu H. Estey. (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer 92:8, pages 1999-2015.
Crossref
RA Larson. (2001) New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia 15:4, pages 675-676.
Crossref
Francis Giles, Jorge Cortes, Guillermo Garcia-Manero, Stephen Kornblau, Elihu Estey, Monica Kwari, Anthony Murgo & Hagop Kantarjian. (2001) Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia. Investigational New Drugs 19:1, pages 13-20.
Crossref
MILOSLAV BERAN & HAGOP M. KANTARJIAN. (2006) Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies. Annals of the New York Academy of Sciences 922:1, pages 247-259.
Crossref
Roger Dansey. (2000) Myelodysplasia. Current Opinion in Oncology 12:1, pages 13-21.
Crossref
Denzlinger, Bowen, Benz, Gelly, Brugger & Kanz. (2001) Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia. British Journal of Haematology 108:1, pages 93-95.
Crossref
Miloslav BeranElihu EsteySusan O'BrienJorge CortesCharles A. KollerFrancis J. GilesSteven KornblauMichael AndreeffNorbert VeySherry R. PierceKimberly HayesGee Chuan WongMichael KeatingHagop Kantarjian. (1999) Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology 17:9, pages 2819-2819.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.